Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Choosing between stem cell therapy and drugs in myelofibrosis.

Kröger N, Mesa RA.

Leukemia. 2008 Mar;22(3):474-86. doi: 10.1038/sj.leu.2405080. Review.

PMID:
18185525
2.

Allogeneic hematopoietic cell transplantation in myelofibrosis with myeloid metaplasia.

Hogan WJ, Litzow MR, Tefferi A.

Curr Hematol Malig Rep. 2007 Feb;2(1):34-42. doi: 10.1007/s11899-007-0005-3. Review.

PMID:
20425386
3.
4.

Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis.

Slot S, Smits K, van de Donk NW, Witte BI, Raymakers R, Janssen JJ, Broers AE, Te Boekhorst PA, Zweegman S.

Bone Marrow Transplant. 2015 Nov;50(11):1424-31. doi: 10.1038/bmt.2015.172.

PMID:
26237165
5.

No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis.

Ditschkowski M, Elmaagacli AH, Trenschel R, Steckel NK, Koldehoff M, Beelen DW.

Biol Blood Marrow Transplant. 2006 Dec;12(12):1350-1. No abstract available.

6.

Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis.

Mesa RA, Tefferi A.

Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9. doi: 10.1517/14728210903066809. Review.

PMID:
19552608
7.

Allogeneic stem cell transplant vs.Janus kinase inhibition in the treatment of primary myelofibrosis or myelofibrosis after essential thrombocythemia or polycythemia vera.

Alchalby H, Kröger N.

Clin Lymphoma Myeloma Leuk. 2014 Sep;14 Suppl:S36-41. doi: 10.1016/j.clml.2014.06.012. Review.

PMID:
25486953
8.

New drugs for the treatment of myelofibrosis.

Mesa RA.

Curr Hematol Malig Rep. 2010 Jan;5(1):15-21. doi: 10.1007/s11899-009-0037-y. Review.

PMID:
20425392
10.

MPN blast phase: clinical challenge and assessing response.

Mesa RA, Tibes R.

Leuk Res. 2012 Dec;36(12):1496-7. doi: 10.1016/j.leukres.2012.08.026. No abstract available.

PMID:
22999527
11.

Reduced-intensity conditioning followed by allogeneic hematopoietic stem cell transplantation in myelofibrosis.

Alchalby H, Kröger N.

Curr Hematol Malig Rep. 2010 Apr;5(2):53-61. doi: 10.1007/s11899-010-0044-z. Review.

PMID:
20425397
12.
13.

Allogeneic hematopoietic stem cell transplantation for myelofibrosis.

Barosi G, Bacigalupo A.

Curr Opin Hematol. 2006 Mar;13(2):74-8. Review.

PMID:
16456372
14.

Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia.

Mesa RA, Quintás-Cardama A, Verstovsek S.

Curr Hematol Malig Rep. 2007 Feb;2(1):25-33. doi: 10.1007/s11899-007-0004-4. Review.

PMID:
20425385
15.

Autologous reconstitution leading to sustained JAK2-V617F negativity post allogeneic hematopoietic stem cell transplant in JAK2-V617F positive myelofibrosis.

Torka P, Hahn T, Bertolo J, Liu H, Ross M, Paplham P, Jankowski A, Deeb G, Chen G, McCarthy P.

Bone Marrow Transplant. 2015 Nov;50(11):1480-2. doi: 10.1038/bmt.2015.169. No abstract available.

PMID:
26214139
16.

Allogeneic stem cell transplantation for myelofibrosis in 2012.

McLornan DP, Mead AJ, Jackson G, Harrison CN.

Br J Haematol. 2012 May;157(4):413-25. doi: 10.1111/j.1365-2141.2012.09107.x. Review.

PMID:
22463701
17.

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Kröger N, Holler E, Kobbe G, Bornhäuser M, Schwerdtfeger R, Baurmann H, Nagler A, Bethge W, Stelljes M, Uharek L, Wandt H, Burchert A, Corradini P, Schubert J, Kaufmann M, Dreger P, Wulf GG, Einsele H, Zabelina T, Kvasnicka HM, Thiele J, Brand R, Zander AR, Niederwieser D, de Witte TM.

Blood. 2009 Dec 17;114(26):5264-70. doi: 10.1182/blood-2009-07-234880.

18.

Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.

Cook G, Smith GM, Kirkland K, Lee J, Pearce R, Thomson K, Morris E, Orchard K, Rule S, Russell N, Craddock C, Marks DI; Clinical Trials Committee (CTC) of the British Society for Blood and Marrow Transplantation (BSBMT)..

Biol Blood Marrow Transplant. 2010 Oct;16(10):1419-27. doi: 10.1016/j.bbmt.2010.04.006.

19.

Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need.

Shimoni A, Nagler A.

Best Pract Res Clin Haematol. 2011 Sep;24(3):369-79. doi: 10.1016/j.beha.2011.05.002. Review.

PMID:
21925090
20.
Items per page

Supplemental Content

Support Center